APAdrianna Pielech

Adrianna Pielech

*This is an algorithmically generated author record based on publicly available information.

Adrianna Pielech has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    When should you suspect if your patient is an Anabolic-Androgenic Steroid User? Evidence-Based literature review of usage patterns changes and clinical implications for medical practice (2005-2025)

    by Adrianna Pielech, Patrycja Dadyńska, Marek Wilczyński, Paweł Kwiecień, Michał Kwiecień, Julianna Zielska

    Background: Anabolic-androgenic steroid (AAS) use has evolved into a significant public health concern affecting diverse populations beyond elite athletics. Objective: To examine evidence-based changes in AAS usage patterns including demographics, motivations, and health consequences from 2005-2025 using systematic reviews and peer-reviewed research. Methods: Literature review of peer-reviewed studies and systematic reviews from PubMed and National Health Institute Library focusing on AAS epidemiology, demographic changes, and health consequences published between 2005-2025. Results: Global lifetime prevalence of AAS use is estimated at 6-29%. Female participation is estimated to be constantly growing. Evidence indicates expansion beyond traditional athletic populations with significant cardiovascular, psychiatric, and reproductive health consequences. Conclusions: AAS use represents a widespread public health concern requiring enhanced clinical awareness and evidence-based management approaches among medical practitioners.

  • Open Access

    VITAMIN D — THE IMPACT ON DEVELOPMENT AND TREATMENT OF ATRIAL FIBRILLATION

    by Julianna Zielska, Eliza Gawron, Paweł Liszka, Aleksandra Kaniak, Kacper Forszt, Adrianna Pielech, Ewa Turczyn, Julia Andrzejewska, Dominika Ziółkowska, Agata Ogórek

    Introduction: Atrial fibrillation is the most common cardiac arrhythmia affecting approximately 700 thousand Polish people. In Poland, insufficient vitamin D levels are highly prevalent and concern around 90% of the population. Except the established, modifiable risk factors of AF, new risk factors such as vitamin D deficiency are being described. Some potential mechanisms involving vitamin D in atrial fibrillation pathogenesis include: cardiac remodelling via the vitamin D receptor, modulation of renin-angiotensin-aldosterone system, influence on parathyroid hormone concentration, changes in action potential duration and left atrium contractility, and activation of proinflammatory pathway by low vitamin D levels. Aim of the study: This review aims to analyze the potential relationship between vitamin D concentration and the risk of developing atrial fibrillation based on the current state of knowledge (as of 2025). Moreover, we tried to examine how vitamin D concentration could influence the efficacy of atrial fibrillation treatment methods such as cardioversion or ablation. Material and Methods: This review is based on literature from 2011 to 2024, searched in PubMed, Google Scholar, mp.pl and ClinicalTrials.gov that was describing the results of vitamin D deficiency on atrial fibrillation development and the treatment outcomes. Conclusions: Serum vitamin D concentration may have an impact on both atrial fibrillation onset and its treatment. It is possible that there are several groups of patients among whom the sufficient vitamin D level would be particularly beneficial. Further studies, especially those focusing on vitamin D supplementation, are needed to clarify the role of vitamin D in atrial fibrillation pathogenesis and treatment.

  • Open Access

    The Advancement Stage of Gastric Cancer and the Levels of CEA and Ca19-9 in Serum and Peritoneal Lavage

    by Michał Bąk, Magdalena Wojciech, Adrianna Pielech, Sylwia Holka, Marek Zawadzki, Dawid Murawa

    Background: This study aimed to analyze the relationship between the levels of tumor markers—specifically, carcinoembryonic antigen (CEA) and Ca19-9 antigen—determined in both serum (sCEA and sCa19-9) and intraoperative peritoneal washings (pCEA and pCa19-9) and the advanced stage of gastric cancer (including the occurrence of cancer cells in cytology from abdominal fluid). Methods: This study included 47 patients with histopathologically confirmed gastric cancer or gastroesophageal junction cancer who underwent surgical treatment. The material for the cytological examination and assessment of CEA and Ca19-9 concentrations in peritoneal fluid was collected intraoperatively. Later, blood was drawn to assess the CEA and Ca19-9 concentrations in blood serum. Results: There was a statistical correlation between a positive cytology result or the presence of peritoneal carcinomatosis and a positive result for the tumor markers obtained from abdominal washings. This correlation was not observed with marker levels obtained from blood serum. The pCEA marker was highly sensitive (93.3%) and specific (93.8%) for detecting cancer cells. The pCa19-9 marker was less effective in detecting cancer but matched pCEA in identifying the absence of cancer. No differences were observed in sCEA and sCA19-9 levels between patients who underwent neoadjuvant chemotherapy and those who did not receive this treatment. However, statistical analysis showed that this relationship did not apply to pCEA and pCa19-9 levels. Conclusions: Intraoperative determinations of tumor marker levels in peritoneal washings may be a predictive factor for a poor prognosis in patients with gastric cancer.